Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. EJE PRIZE 2018: A gut feeling about glucagon

    Research output: Contribution to journalReviewResearchpeer-review

  4. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. High maternal age at first and subsequent child births in Denmark in the mid-1800s-Letter to the editor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Characterisation and localisation of the endocannabinoid system components in the adult human testis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characterization of Human Adrenal Steroidogenesis during Fetal Development

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Populations, decreasing fertility, and reproductive health

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The acute metabolic actions of purified human growth hormone (GH) were first documented in adult hypopituitary patients more than 50 years ago, and placebo-controlled long-term GH trials in GH-deficient adults (GHDA) surfaced in 1989 with the availability of biosynthetic human GH. Untreated GHDA is associated with excess morbidity and mortality from cardiovascular disease and the phenotype includes fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia and elevated levels of circulating cardiovascular biomarkers. Several of these features reverse and normalize with GH replacement. It remains controversial whether quality of life, assessed by questionnaires, improves. The known side effects are fluid retention and insulin resistance, which are reversible and dose dependent. The dose requirement declines markedly with age and is higher in women. Continuation of GH replacement into adulthood in patients with childhood-onset disease is indicated, if the diagnosis is reconfirmed. GH treatment of frail elderly subjects without documented pituitary disease remains unwarranted. Observational data show that mortality in GH-replaced patients is reduced compared to untreated patients. Even though this reduced mortality could be due to selection bias, GH replacement in GHDA has proven beneficial and safe.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume179
Issue number1
Pages (from-to)R47-R56
ISSN0804-4643
DOIs
Publication statusPublished - Jul 2018

    Research areas

  • Body Composition, Bone Diseases, Metabolic/etiology, Exercise Tolerance, Hormone Replacement Therapy, Human Growth Hormone/deficiency, Humans, Hypopituitarism/complications, Insulin Resistance, Obesity, Abdominal/etiology, Quality of Life, Recombinant Proteins/therapeutic use, Treatment Outcome, Water-Electrolyte Imbalance/chemically induced

ID: 56535544